2,523
Views
33
CrossRef citations to date
0
Altmetric
Research Article

Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking

, , , , &
Pages 777-783 | Received 16 Mar 2011, Accepted 13 Apr 2011, Published online: 18 Jul 2011

Figures & data

Figure 1. Transversal images through the level of the basal ganglia of a patient with glioblastoma multiforme. The T1 weighted MR after contrast injection (left image) show a central area in the left temporal lobe with contrast enhancement. The metabolic activity in temperature scale using FDG-PET (right image). The tumor region – the large red region with the highest uptake – extends far beyond the MR contrast enhanced area in all directions, as shown in the fused images (centre image).

Figure 1. Transversal images through the level of the basal ganglia of a patient with glioblastoma multiforme. The T1 weighted MR after contrast injection (left image) show a central area in the left temporal lobe with contrast enhancement. The metabolic activity in temperature scale using FDG-PET (right image). The tumor region – the large red region with the highest uptake – extends far beyond the MR contrast enhanced area in all directions, as shown in the fused images (centre image).

Figure 2. Left: transversal CT image with overlaid tractography structure in gold. The hippocampi and brainstem are displayed in purple and green, respectively. Right: a 3D fiber tract structure seen anteriorly with eyes in red and green for the same patient. Fibers are displayed in red, green and blue in the images. The color coding is by convention red for commissural (transversal) tracts, blue for fibers running superoinferiorly and green for fibers running in ventralodorsaly. The fibers were disrupted and displaced by the tumor, as indicated by the lack of symmetry in both images.

Figure 2. Left: transversal CT image with overlaid tractography structure in gold. The hippocampi and brainstem are displayed in purple and green, respectively. Right: a 3D fiber tract structure seen anteriorly with eyes in red and green for the same patient. Fibers are displayed in red, green and blue in the images. The color coding is by convention red for commissural (transversal) tracts, blue for fibers running superoinferiorly and green for fibers running in ventralodorsaly. The fibers were disrupted and displaced by the tumor, as indicated by the lack of symmetry in both images.

Figure 3. Doses to the organs at risk specifically evaluated in this study. Average doses for the 15 patients (Fiber Objects were averaged for 5 patients) are presented.

Figure 3. Doses to the organs at risk specifically evaluated in this study. Average doses for the 15 patients (Fiber Objects were averaged for 5 patients) are presented.

Figure 4. The ranges of the standard deviations of the absorbed doses to the Planning Target Volumes for the Intensity Modulated photon Radiation Therapy (IMRT), coplanar RapidArc (RA), non-coplanar RA and Intensity Modulated Proton Therapy (IMPT) techniques are shown as lines in the diagram. The extent of the boxes represent the range of the mid third of the standard deviations for each radiation therapy technique.

Figure 4. The ranges of the standard deviations of the absorbed doses to the Planning Target Volumes for the Intensity Modulated photon Radiation Therapy (IMRT), coplanar RapidArc (RA), non-coplanar RA and Intensity Modulated Proton Therapy (IMPT) techniques are shown as lines in the diagram. The extent of the boxes represent the range of the mid third of the standard deviations for each radiation therapy technique.

Figure 5. Example dose distribution for one patient: IMRT (left), IMPT (mid-left), RA (mid-right) and non-coplanar RA (right). The color-wash shows the dose distribution in temperature scale from 110% to 10% of the prescription level (60 Gy).

Figure 5. Example dose distribution for one patient: IMRT (left), IMPT (mid-left), RA (mid-right) and non-coplanar RA (right). The color-wash shows the dose distribution in temperature scale from 110% to 10% of the prescription level (60 Gy).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.